Introduction and Aims: The aim of our study was to put some light on the epidemiology of renal diseases in the population of individuals aged ≥65 years.

Methods: between January 2009 and November 2014 all of the native kidney biopsies from patients aged ≥65 years that were evaluated in Medical University of Warsaw were identified and analyzed in the context of clinical data.

Results: Among all 2527 native kidney biopsies evaluated in an analyzed period there were 353 (14%) biopsies from patients aged ≥65 years. The leading indications for the biopsy were: nephrotic range proteinuria (54% of elderly and 43% of younger patients) and nonnephrotic proteinuria (32% in elderly and 48% in younger patients) with or without associated erythrocyturia.

At the time of biopsy 73% of patients aged ≥65 years and 45% of younger individuals had eGFR (according to MDRD formula) below 60 ml/min.

Of all kidney biopsies performed in patients ≥65 years of age the most common among pathologic recognitions were: membranous GN (MGN) (18%), FSGS (16%) and amyloidosis (14%), which was in contrast to the population of patients aged 18-64 years, in which the leading pathologic diagnoses were: IgA nephropathy (27%), FSGS (15%) and MGN (10%). Among patients aged ≥65 years with nephrothic range proteinuria the most common pathologic recognitions were: MGN (25%), amyloidosis (21%) and FSGS (17%), whereas in younger patients nephrotic proteinuria was most commonly related to MGN (17%), FSGS (17%) and minimal change disease (12%). As for non-nephrotic proteinuria in individuals aged ≥65 years the three dominating diagnoses were: pauci immune crescentic GN (16%), IgA nephropathy (16%) and FSGS (15%), whereas in population aged 18-64 most common diagnoses were: IgA nephropathy (35%), FSGS (13%) and lupus nephritis.

Conclusions: Our analysis revealed differences in the prevalence of some of kidney diseases between elderly patients and younger individuals. The performance of kidney biopsy in elderly patients with proteinuria allows for the implementation of targeted, and not only nephroprotective treatment in severe, and relatively frequent medical conditions as amyloidosis and crescentic GN

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.